Cellectis (ALCLS.PA)

Cellectis stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · Euronext Paris · France

€0.975▲ +3.84%

Prices as of Oct 27, 2026 · EUR

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

46%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Cellectis in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Cellectis

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Cellectis a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between €0.845 and €1.09; in 9 out of 10, between €0.676 and €1.36. Estimated annual volatility is 74%.

Price, last 12 months (weekly close)

Key numbers

Market cap: €109M
Market cap (USD): $121M
52-week high: €4.75
52-week low: €0.895
Revenue (12 months): $63.8M
Operating margin: -340.7%
Net margin: -102.3%
Beta: 2.91

What this means

ATLAS does not publish a fair value for ALCLS.PA right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks ALCLS.PA has traded between €0.895 and €4.75. Today it is 79.5% below that high and 9% above its low.

Its beta is 2.91: it tends to move more than the market, both up and down.

About the company

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Want to see everything about Cellectis?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Cellectis do?

What is the chance ALCLS.PA goes up next month?

46%: close to a coin flip. In half of the simulated outcomes, ALCLS.PA ends the month between €0.845 and €1.09.

How big is Cellectis and what is its P/E ratio?

Cellectis's market capitalization is €109M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is ALCLS.PA?

ATLAS estimates annual volatility at 74%. In a typical month, half of the outcomes end between €0.845 and €1.09.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer